Proteomic characterization of an isolated fraction of synthetic proteasome inhibitor (PSI)-induced inclusions in PC12 cells might offer clues to aggresomes as a cellular defensive response against proteasome inhibition by PSI
© Li et al; licensee BioMed Central Ltd. 2010
Received: 11 October 2009
Accepted: 12 August 2010
Published: 12 August 2010
Cooperation of constituents of the ubiquitin proteasome system (UPS) with chaperone proteins in degrading proteins mediate a wide range of cellular processes, such as synaptic function and neurotransmission, gene transcription, protein trafficking, mitochondrial function and metabolism, antioxidant defence mechanisms, and apoptotic signal transduction. It is supposed that constituents of the UPS and chaperone proteins are recruited into aggresomes where aberrant and potentially cytotoxic proteins may be sequestered in an inactive form.
To determinate the proteomic pattern of synthetic proteasome inhibitor (PSI)-induced inclusions in PC12 cells after proteasome inhibition by PSI, we analyzed a fraction of PSI-induced inclusions. A proteomic feature of the isolated fraction was characterized by identification of fifty six proteins including twenty previously reported protein components of Lewy bodies, twenty eight newly identified proteins and eight unknown proteins. These proteins, most of which were recognized as a profile of proteins within cellular processes mediated by the UPS, a profile of constituents of the UPS and a profile of chaperone proteins, are classed into at least nine accepted categories. In addition, prolyl-4-hydroxylase beta polypeptide, an endoplasmic reticulum member of the protein disulfide isomerase family, was validated in the developmental process of PSI-induced inclusions in the cells.
It is speculated that proteomic characterization of an isolated fraction of PSI-induced inclusions in PC12 cells might offer clues to appearance of aggresomes serving as a cellular defensive response against proteasome inhibition.
The ubiquitin proteasome system (UPS) involves a serial enzymatic cascade of ubiquitin dependent protein degradation through which to prevent aberrant and potentially cytotoxic proteins from forming insoluble protein aggregates . Chaperones are a group of protein folding catalysts and protein transporters which also emerge as active participants in protein degradation . Cooperation of constituents of the UPS with chaperone proteins mediate a wide range of cellular processes, such as synaptic function and neurotransmission, gene transcription, protein trafficking, mitochondrial function and metabolism, antioxidant defence mechanisms, and apoptotic signal transduction [3–5]. Dysfunction of the UPS has been implicated in protein aggregation as a possible cause for pathogenesis in a number of the age-related neurodegenerative and chronic neurological disorders . Parkinson's disease (PD) viewed as a representative of these disorders is characterized by selective death of dopaminergic neurons in the substantia nigra pars compacta (SNpc) and by appearance of abundant proteinaceous inclusions known as Lewy bodies (LBs) .
One of current concepts in PD pathogenesis is to understand the mechanism of LBs. Protein aggregation has been demonstrated to play the role in the developmental stages of LBs at cellular and molecular levels [8, 9]. Substantial progress has been made in understanding of the mechanism for LBs, aggresome-related process [10, 11]. According to this hypothesis, dysfunction of the UPS contributes to aggregation of aberrant and potentially cytotoxic proteins into insoluble protein aggregates. One protective way cells handle the species of aggregated proteins is to compartmentalize them in specialized inclusions called as aggresomes [12, 13]. The aggresome machinery is activated as the last resort if constituents of the UPS and chaperone proteins fail to reverse increasing level of the target proteins through transient up-regulation of gene expression in the stressful environment [14–16]. It is supposed that constituents of the UPS and chaperone proteins are recruited into aggresomes where aberrant and potentially cytotoxic proteins may be sequestered in an inactive form [17, 18].
However, proteins in aggresomes are to be revealed if we elaborate on possible causation of formation of LBs: largely owing to dysfunction of the UPS. Currently, the proteomic analysis of proteinaceous inclusions, whether for patients with PD or in vitro models of PD due to disruption of mitochondria, offers a valuable tool to study protein composition of aggresomes [19, 20]. Traditionally, cellular fractionation has provided the means to isolate a fraction of LBs from brain tissue of LB variant of Alzheimer's disease patients . Therefore, an isolated fraction of inclusions as the starting material is suitable for proteomic analysis . Although it remained to be determined that LBs are bona fide in vivo correlates of aggresomes , aggresomes and LBs are similar in protein composition as well as morphological structures . At least, on the premise of the inducible aggresomes in cultured cells  and the emphasized purity and yield of organelles isolated through cellular fractionation of samples , proteomic characterization of inclusions can advance our knowledge about nature of aggresomes .
The aim of this present work was to determinate the proteomic pattern of proteasome inhibitor (PSI)-induced inclusions formed in PC12 cells after proteasome inhibition by PSI. Our main results were that a fraction of PSI-induced inclusions isolated from the cells was qualified for proteomic analysis and that a proteomic feature of the isolated fraction was characterized by the identification of fifty six proteins.
Evaluation of cell survival
Evaluation of a procedure of cellular fractionation
Using the hematoxylin-eosin (H&E) histological staining, we detected the eosinophilic PSI-induced inclusions in the cells with exposure to PSI for 48 h. Compared to the cells in the vehicle which were shown without no morphological change in eosinophilic structure (Figure 1B:a), the cells in PSI were shown with distinct eosinophilic inclusions (Figure 1B:b). Further, similar to inducible inclusions from PC12 cells in PSI for 24 h or MES cells in mitochondrial respiratory chain complex I inhibitor, rotenone for 72 h [19, 24], the PSI-induced inclusions appeared with a focal, homogeneous shape and displayed two types of morphology: nucleus-binding and nucleus-free inclusions. It was assumed that some of the PSI-induced inclusions were observed in the cytoplasm of the remaining cells, whereas the others were extruded into the extracellular space after destruction of the host cells .
At the first stage of isolation, using the H&E histological staining, we detected the eosinophilic PSI-induced inclusions, collected in the fraction of initial pellets. By homogenization of the cells with 0.5% NP-40 at 37°C for 30 min and subsequent centrifugation at 80 × g for 15 min, an abundance of intact PSI-induced inclusions (Figure 1B:c) was yielded. In practice, we also increased the number of nucleus-free PSI-induced inclusions. There was a significant difference in the percentage of the nucleus-free to total PSI-induced inclusions between the fraction of cells in PSI (51%; Figure 1B:d, Column 1) and the fraction of initial pellets (69%; Figure 1B:d,Column 2), *P < 0.05.
At the second stage of isolation, using the H&E histological staining, we first detected the PSI-induced inclusions, collected in the temporary and final fractions of resulting pellets. By four time-dependent incubations of the initial pellets with 200 U/ml DNase I at 37°C for different lengths of time during the 24 h period, the increasing number of nucleus-free PSI-induced inclusions were easily yielded at the cost of the gradual decline of nucleus-binding PSI-induced inclusions, and of which, when the one of the time-dependent incubations ran out for the entire 24 h, the increase of nucleus-free PSI-induced inclusions instead of the decline of nucleus-binding PSI-induced inclusions could be most easily yielded. In detail, after the four time-dependent incubations for 1 h (Figure 1B:e), 6 h (Figure 1B:f), 12 h (Figure 1B:g) and 24 h (Figure 1B:h), the inclusive regions of nucleus (close arrow heads) but not the inclusive regions of inclusion (open arrows) within the nucleus-binding PSI-inclusions were progressively reduced. The percentage of the nucleus-free to total PSI-induced inclusions in the temporary fraction of resulting pellets which was collected after the one of the four time-dependent incubations of the initial pellets for 1 h (79%; Figure 1B:j Column 3) differed significantly from each of the percentages in the temporary fractions of resulting pellets which were collected after the other three of the four time-dependent incubations of the initial pellets for 6 h (80%; Figure 1B:j Column 4), 12 h (81%; Figure 1B:j Column 5) and 24 h (93%; Figure 1B:j Column 6), *P < 0.05. Interestingly, by the incubation of the initial pellets with 200 U/ml DNase I and 250 μg/ml RNase A for 24 h, a large quantity of nucleus-free PSI-induced inclusions instead of few nucleus-binding PSI-induced inclusions was observed in the final fraction of resulting pellets (Figure 1B:i). All percentages in the first four temporary fractions of resulting pellets (Figure 1B:j, Column 3-6) differed significantly from the percentage in the final one (97%; Figure 1B:j Column 7), **P < 0.05.
At the second stage of isolation, we detected the alpha synuclein (alpha-SYN) positive, eosinophilic inclusions, collected in the isolated fraction of PSI-induced inclusions, using the alpha-SYN immunostaining and the H&E histological staining, and then detected the relatively small amount of histone H1 present in the same fraction using the West blotting for histone H1, one of the most abundant proteins in the nucleus [26, 27]. In general, subcellular particles, such as cellular debris and technical artifacts, were created after the homogenization at the first stage of isolation, and in particular, nuclear proteins were remained after the nucleus degradation at the second stage of isolation. Thus, by centrifuging the final fraction of resulting pellets in discontinuous Percoll-mediated 12%-35% gradients at 35,000 × g for 30 min, the intact PSI-induced inclusions could be easily divided from these subcellular particles and collected as preparation of the target fraction. On one hand, whether the PSI-induced inclusions were formed in the cells in PSI (Figure 1C:a and 1C:a') or isolated through cellular fractionation (Figure 1C:b and 1C:b'), they were stained as alpha-SYN positive, eosinophilic structures. On the other hand, in comparison to the intensive signal of blotted histone H1 in gel image and its high level in the column diagram, both of which were characteristic of the large amount of nuclear proteins for the samples of the cells in the vehicle or in PSI, the faint signal of blotted histone H1 in gel image and its low level in column diagram were characteristic of the trace of nuclear proteins for the sample of the isolated fraction of PSI-induced inclusions (Figure 1D:a and 1D:b). In the end, the pure intact PSI-induced inclusions were found in the isolated fraction.
Two-dimensional (2-D) gel-based protein resolution
It is pointed out that values of both molecular mass and pI supplied in a matrix-assisted laser desorption/ionization time-of-flight (MALDI-TOF) mass spectrometry (MS) data file are usually theoretical. Some of the spots identified as proteins were found to alter their positions across 2-D gel in the present experimental condition. In general, the observed difference most probably reflects mechanisms for the augmentation of ubiquitin fusion-protein expression in eukaryotes when proteasomes are inhibited beyond a threshold level [32–34].
PMF-base protein identification
We detected experimental PMF spectra of the target protein spots using MALDI-TOF MS, and then PMF data for protein identification using two on-line proteomic search engines. Preliminarily, a total of fifty six proteins were identified after submission of their PMFs to the ProPound search engine against the single NCBInr database (shown in Additional file 1). Furthermore, forty eight of the fifty six proteins were consistently identified after submission of their PMFs to the Mowse score-based Mascot search engine against the multiple NCBInr, SwissProt, MSDB databases (shown in Additional file 1). For example, prolyl-4-hydroxylase beta subunit (P4HB) identified via its PFM against the single database is shown with a group of MS data, such as 32.4% sequence coverage, 0.000 expectation, 8 matched peptides and theoretic sequences of the matched peptides (Figure 2B:a and 2B:b). After consistent identification via its PFM against the multiple databases, it was shown with its three comparable score values, viz., a top score value of 71 (> 61) compared to a runner up value of 38 (< 61) for NCBInr branch, 71 (> 51) compared to 37 (< 51) for SwissProt branch, and 71 (> 56) compared to 38 (< 56) for MSDB branch (Figure 2B:c to 2B:e). The protein was ultimately determined.
In this study, proteasome inhibition by PSI induced cell death and formation of inclusions in PC12 cells. An end point cell death estimated using trypan blue exclusion assay confirmed the effect of proteasome inhibition by PSI on survival of the cells. Cytoplasmic eosinophilic PSI-induced inclusions in the cells were immunostained to visualize alpha-SYN positive structures. Experimental observations have been providing evidence that application of proteasome inhibitors such as lactacystin and (or) PSI to PC12 cells is closely associated with both cell death and formation of inclusions [49–52]. Nevertheless, low doses of PSI which produces the highest number of inclusions in PC12 are not enough to induce massive cell death in the cells, whereas increasing its doses lead to mass damage of the cells which does not allow the visualization of inclusions [24, 52], as shown similarly in PC12 cells with exposure to methamphetamine . Thus, the administration of PSI to PC12 cells we selected could induce the abundance of cytoplasmic inclusions as well as a massive amount of cell death. Besides, morphological maturation of the PSI-induced inclusions could allow us to appreciate how their isolation was achieved.
In the study, we developed a three-process fractionation procedure to isolate a fraction of PSI-induced inclusions from the cell culture model of PD, and thereafter characterized a proteomic feature of the isolated fraction. Traditional fractionation for isolating any population of organelles from cell cultures consists of two major stages: homogenization of cell cultures to release various populations of intact organelles, and fractionation of homogenate to isolate the population of targeted organelles . At the first stage of isolating PSI-induced inclusions, a first process of fractionation procedure was used to separate the abundance of nucleus-binding and the nucleus-free PSI-induced inclusions into the fraction of initial pellets. At the second stage of isolation, a second process of fractionation procedure was used to increase the nucleus-free PSI-induced inclusions at the cost of declining the nucleus-binding PSI-induced inclusions, after which the whole PSI-induced inclusions were enriched into the fraction of resulting pellets; in the next isolation, a third process of fractionation procedure was used to purify PSI-induced inclusions into the preparation of target fraction. In the case of the target fraction that should be prepared as starting material sufficient for proteomic analysis, the 2-D gel-based protein resolution and the PMF-based protein identification were used to define a proteomic feature of the isolated fraction of PSI-induced inclusions. Of a total of fifty six proteins identified, twenty proteins such as TH were found to be previously reported protein components of LBs, twenty eight proteins such as eukaryotic elongation factor 2 (eEF-2) were newly identified, and the other eight proteins were in lower confidence for information about protein designation. These proteins, most of which were recognized as a profile of proteins within cellular processes mediated by the UPS, such as tubulin alpha 1, a profile of constituents of the UPS, such as PSMC2, and a profile of chaperone proteins, such as HSP27, are classed into at least nine accepted categories. In addition, P4HB, an ER member of the PDI family, was biologically validated in the developmental process of PSI-induced inclusions in PC12 cells after proteasome inhibition by PSI.
In nerve endings and particularly brain neurons, it is likely that proteins are easily damaged owing to limitation of intrinsic ability for repair and (or) regeneration, level of relatively high oxygen and elevated metabolic rate, and enzymatic- and auto-oxidation of neurotransmitters such as DA. Protein degradation via the UPS exerts an effect on the removal of damaged proteins that are extensively linked to cellular processes, such as synaptic function and neurotransmission (I), gene transcription (II), protein trafficking (III), mitochondrial function and metabolism (IV), antioxidant defense mechanisms (V), apoptotic signal transduction (VI) . Cooperation of constituents of the UPS (VII) with chaperone proteins (VIII) in protein degradation plays the central role in these processes [53, 54].
I. TH identified in the study is regulated at two levels: a long-term regulation involves changes in enzyme synthesis for several days, while a short-term regulation of enzyme activity is arrested by direct phosphorylation of the protein within several minutes . Alpha-SYN diminishes TH phosphorylation and activity in stably transfected dopaminergic cells . Given that alpha-SYN aggregation is induced by proteasome inhibitors  and that TH is degraded through the UPS [57, 58], it is not coincidence that TH colocalizes with alpha-SYN in LBs .
II. eEF-2 identified in the study is one of the gene transcription factors whose cellular level in protein turnover process is dependent on the UPS . Proteasome inhibition by proteasome inhibitors in cells activates up-regulation of specific members of transcription factor families controlling cellular stress response . Transcription factors may be trapped by cytoplasmic protein aggregates in response to proteasome inhibition [61, 62]. In addition, eEF-2 is phosphorylated by specific eEF-2 kinase causing its complete inactivation , and relevance of transient eEF-2 kinase to the UPS may define cellular levels of eEF-2 between dephosphorylation and phosphorylation . Potentially phosphorylated eEF-2 might acquire aggregation competence in PC12 cells after proteasome inhibition by PSI.
III. Tubulin alpha1 and tubb5 identified in the study not only colocalize with alpha-SYN in LBs or other alpha-SYN positive pathological structures, but also initiate alpha-SYN fibril formation under pathological conditions in vitro . The binding between parkin and tubulin led to increased ubiquitination and accelerated degradation of alpha- and beta-tubulins in vitro .
IV. The UPS can influence mitochondria under pathologic conditions . Proteasome inhibition by proteasome inhibitors not only increases the generation of reactive oxygen species (ROS) in mitochondria [67, 68], but also activates the compartmentalization of mitochondrial proteins in aggresomes . The two mitochondrial proteins identified in the study and found as components of LBs, F1-ATPase beta and Uqcrc1, might be damaged by mitochondrial ROS.
V. Antioxidant enzyme C, Z-SOD identified in the study is the most notable component of antioxidant protective defense system in response to oxidative stress by both SOD mechanism and hydrogen peroxide system mediated-protein modification [70–72]. Proteasome inhibition by proteasome inhibitors has been shown to generate oxidative stress in vitro and potentiate compensatory up-regulation of antioxidants as a protective mechanism against oxidative stress [14, 73, 74]. The oxidative modification of C, Z-SOD is associated with PD .
VI. Apoptosis is the major mechanism of neuronal death in PD. Apoptotic response is quantified by all members of the annexin family, especially annexin V [14, 76]. Three members of the annexin family were identified in the study. Proteasome inhibition by proteasome inhibitor MG-132 in a dopaminergic neuronal cell model (N27 cells) rapidly depolarized mitochondria independent of ROS generation to activate the apoptotic cascade . Aggresomes may be viewed as the wrong cellular compartments where apoptotic cascade proteins are sequestered after detrimental effects of proteasome inhibition by proteasome inhibitors on mitochondrial homeostasis .
VII. Proteasomal subunits are in progress of the tightly coordinated expression and integrated assembly under physiological conditions [79, 80]. However, under proteolytic stress conditions elicited by proteasome inhibitors, proteasomal subunits display the alterable profile of expression and composition [14, 81]. For example, treatment of cells with proteasome inhibitors activates a transient up-regulation of mRNAs of all proteasomal subunits . The alteration might represent a regulatory feedback mechanism attempting to reverse proteasome inhibition [80, 83], but if the compensatory regulation fails to establish affection, proteasomal subunits are recruited to aggresomes to ubiquitinate and degrade protein (Figure 5) [11, 42]. One beta subunit of 20 S proteasome core particle and five ATPase-dependent and ATPase-independent subunits of 19 S proteasome regulatory particle were identified in the study, but it is not known whether proteasomal subunits rich in LBs exist as individual subunits or as part of the intact complex [23, 84, 85].
VIII. Cells usually express diverse family members of chaperones and different versions of a family member of chaperones to block protein aggregation [2, 86]. The chaperone proteins identified in the study own their specialized protein similarities. The intra- and inter-specific species of chaperones are listed by chaperone proteins rich in LBs, such as members of the HSP70 family (in particular, HSP70 and HSC70) and members of the small HSP family (in particular, HSP27 and HSP32) [11, 23, 43, 44]. In substance, proteasome inhibition by proteasome inhibitors increased initial and concerted expression of major types of chaperone proteins in cytoplasm, ER and mitochondria [61, 87, 88]. The compensatory induction of chaperone proteins can be beneficial since aggresomes are supposed to recruit both constituents of the UPS and chaperone proteins to facilitate protein clearance within the structures .
A function for chaperone proteins in targeting aberrant and potentially cytotoxic proteins for degradation via the UPS has been established in various ways . In substance, act of the UPS might depend on the cellular compartment-localized chaperone proteins to guide it along proper pathways [89, 90]. What this means is that chaperon proteins in cytoplasm (in particular, TCP-1beta) are required for the ubiquitin proteasome pathway (UPP) , chaperone proteins in ER (in particular, 150-kD oxygen regulated protein) required for the ER associated degradation pathway (ERAD) , and chaperone proteins in mitochondria (in particular, HSP60) required for the mitochondria-associated degradation pathway (MAD) . Diversity of chaperones among cellular localization resources is listed by spatially restricted subset of chaperone proteins, such as cytoplasmic HSP27, ER luminal 78-kD glucose-regulated protein (GRP78) and mitochondrial HSP60 [69, 93–95]. Relevance of chaperone proteins in cytoplasm, ER and mitochondria to cytoplasmic constituents of the UPS establishes multiple routes of the UPS to remove aberrant and potentially cytotoxic proteins [2, 87], but in response to proteasome inhibition, constituents of the UPS in cytoplasm and chaperone proteins in cytoplasm, ER and mitochondria resources, together with the protein substrates of the UPS, are induced and recruited to aggresomes (Figure 5) [11, 87, 90].
P4HB, also known as PDI , is a highly unusual multifunctional polypeptide . As with calcium-binding proteins and GRPs which are two members of the PDI family [92, 98], P4HB acts through ERAD to eliminate proteins unable to adopt native structure after translocation into the ER . On the basis of biological information retrieved from the studies with two model animals, Pongo abelii (accession No., gi|62287145|sp|Q5R5B6.1) and Macaca fuscata fuscata (accession No., gi|110815912|sp|Q2HWU2.1), P4HB has been defined as follows: it acts as a structural subunit of various enzymes, such as proly-4-hydroxylase; it catalyzes the formation, breakage and rearrangement of disulfide bonds; it serves as a natural protector against protein aggregation at high concentration and for protein self-assembly and aggregation at low concentration. Given that up-regulation of the PDI family in dopaminergic neurons might contribute to formation of LBs , and that the formation of LBs may act to delay the initiation of neuronal death and slow progression in sporadic PD, the members of the PDI family identified in the study might expand the defensive role for chaperone proteins in the development of PSI-induced inclusions.
Aggresomes are often enriched with aggresome-related proteins such as chaperone proteins . Next, our task is to establish an immunoblot method for semi-quantitative or quantitative screening of the ten chaperone proteins which were identified in the study but have not been reported in available literatures on LBs. Also, further studies will be required to demonstrate whether or not these proteomic candidates are recruited into aggresomes in response to proteasome inhibition by many other proteasome inhibitors (in particular, lactacystin or MG132). The importance of validation experiments in proteomic analysis and the collection of comparable data from further studies will motivate us to reveal aggresomes in protein content.
Taken together, the fifty six proteins identified by proteomic analysis are associated with the isolated fraction of PSI-induced inclusions in PC12 cells after proteasome inhibition by PSI, and at this stage of the study, it is speculated that proteomic characterization of an isolated fraction of PSI-induced inclusions in PC12 cells might offer clues to appearance of aggresomes serving as a cellular defensive response against proteasome inhibition.
Unless specified otherwise, analytical reagents and reagents of cell culture grade were purchased from Amersham Biosciences (Uppsala, Sweden). PSI, N-benzyloxycarbonyl-Ile-Glu (O-t-butyl)-Ala-Leu-al, was from EMD Biosciences (an affiliate of Merck Chemicals, Darmstadt, Germany). Cell culture plastics, culture media and supplying chemicals were from Gibco (Grand Island, NY, USA). DNase I and RNase A were from TaKaRa Biotechnology (Dalian, China). Percoll (density 1.131 g/ml) and proteinase inhibitors [4-(2-aminoethyl) benzenesulfonyl fluoride, pepstatin A, E-64, bestatin, leupeptin, and aprotinin] were from Sigma (St. Louis, USA). Mouse anti-rat alpha-SYN monoclonal antibody (4D6: sc-65500) and mouse anti-rat histone H1 monoclonal antibody (sc-56694) were from Santa Cruz Biotechnology (California, USA); mouse anti-rat P4HB monoclonal antibody (MAB2073) was from Chemicon (Fuji, Japan). Cy3-conjugated goat anti-mouse secondary antibody (00009-1) was from Proteintech Group (Chicago, USA).
PC12 cells were purchased from Cell Bank of the Chinese Academy of Science (Shanghai, China), and their culture was carried out as described elsewhere .
Proteasome inhibition and cell survival
PC12 cells, seeded at a density of 1 × 105 cells/ml in 96-well plates and incubated for 24 h, were exposed to 10 μM PSI or equal volume of its vehicle, 0.1% DMSO (V/V) in culture medium, for 48 h . Then, they were centrifuged at 1000 rpm (or 93 × g), 4°C for 5 min  and stained with 50 μl of 1% trypan blue (W/V) for 2 min . After supernatant was removed from the cell cultures, living cells at a density of at least 100 cells per field were viewed under an upright fluorescence microscope with IF550 green interference filter in the light path. The number of living cells was counted in nine random fields (three fields per well of a 96-well plate, three different wells) and expressed as a percentage [103, 104]. Chi square test (χ2 test) was used to determine whether a percent difference was significant between the cells without and with PSI exposure. Probability value (P) < 0.05 was accepted as significant. Measurements were repeated at least 3 times.
Formation and isolation of PSI-induced inclusions
Formation of PSI-induced inclusions and their isolation through cellular fractionation were carried out as described elsewhere . Cells exposed to 10 μM PSI were subjected to the H&E histological staining to monitor appearance of the PSI-induced inclusions. Progress in the isolation of PSI-induced inclusions included two sequential stages: separation for an abundant fraction of intact PSI-induced inclusions, and purification for preparation of the target fraction. At the first stage of isolation, briefly, cells in PSI for 48 h were scraped, collected and washed in ice-cold Tris-buffered saline solution (TBS; pH 7.4) and ice-cold 8% sucrose (W/V) in 0.1 × TBS one after the other. The fraction of the cells was frozen repeatedly with liquid nitrogen, and homogenized with a certain amount of lysing buffer consisting of 1 mM Hepes (pH 7.2), 0.5 mM MgCl2, 0.5% NP-40 (V/V), 0.1% beta mercaptoethanol (V/V), and 1% proteinase inhibitors (V/V). After repeated suspension and vibration, the lysate was incubated at 37°C for 30 min until the cells were thoroughly homogenized. Initial pellets were collected by low speed centrifugation at 80 × g for 15 min, washed in ice-cold buffer solution L consisting of 1 mM Hepes, 0.5 mM MgCl2 and proteinase inhibitors, and recollected by centrifugation at 836 × g.
At the second stage of isolation, the fraction of initial pellets was subjected to the H&E histological staining to monitor presence of the eosinophilic PSI-induced inclusion. In the next isolation, four equal aliquots removed from the fraction of initial pellets were incubated in 200 U/ml DNase I alone in DNase I buffer plus proteinase inhibitors at 37°C for 1 h, 6 h, 12 h and 24 h, respectively, whereas another equal aliquot from the fraction was incubated in the DNase I solution with addition of 250 μg/ml RNase A at 37°C for 24 h. In their respective incubations, initial pellets were repeatedly suspended and vibrated vigorously. After incubation, the first four temporary fractions of resulting pellets and the final one were collected by centrifugation at 836 × g, washed with 0.32 M sucrose in TBS, and subjected to the H&E histological staining to monitor presence of the eosinophilic PSI-induced inclusion.
The final fraction of the resulting pellets was diluted to 600 μl using 12% Percoll in TBS (V/V) and overlaid on equal volume of 35% Percoll in TBS. The material band just below the interface of the sample and 35% Percoll was removed, collected by centrifugation at 35,000 × g, washed in 250 mM sucrose in 10 mM Tris (pH 8.0), and recollected by centrifugation at 4000 × g. This isolated fraction of PSI-induced inclusions was the preparation of target fraction. The target fraction was subjected to the α-SYN immunostaining and the H&E histological staining to monitor presence of the PSI-induced inclusion, and then subjected to the Western blotting for histone H1 to monitor contamination of nuclear protein content.
Assessment of PSI-induced inclusions
Eosinophilic PSI-induced inclusions were examined by an experienced observer not familiar with the sample identity. The cells exposed either to the vehicle or to PSI, the fraction of initial pellets, and the five fractions of resulting pellets were all subjected to the H&E histological staining, as previously described . The number of PSI-induced inclusions was counted in nine random fields (three fields per section, three different sections on slide), and expressed as a percentage of nucleus-free to total PSI-induced inclusions. The χ2 test was used to determine whether there was significant difference in the percentage between every two objects of comparison as follows: between the cells in PSI and the fraction of initial pellets, between the first one temporary fraction of resulting pellets and each of the other three temporary fractions of resulting pellets, and between each of the four temporary fractions of resulting pellets and the final fraction of resulting pellets. P < 0.05 was accepted as significant. Measurements were repeated at least three times.
The isolated fraction of PSI-induced inclusions, together with a control (cells in PSI), was first subjected to the alpha-SYN immunostaining and then the H&E histological staining. In the application of immunostaining for alpha-SYN, briefly, the isolated fraction of PSI-induced inclusions was spun on slides and fixed in 4% paraformaldehyde (W/V). Sections on the slides were permeabilized with phosphate-buffered saline containing Triton X-100 (PBS-T; V/V), blocked in 5% bovine serum albumin (BSA; V/V) in PBS for 1 h, incubated with primary antibody at 1:50 dilution in PBS at 37°C for 3 h and incubated with secondary antibody at dilution 1:100 in PBS-T at 37°C for 3 h, and mounted with 80% glycerol (V/V). The dilutions of primary and secondary antibodies were according to the reference to manufacturer's instructions and the description in literature . Control sections were examined, as described above, excluding primary antibody in PBS. Measurements were repeated at least three times.
The isolated fraction of PSI-induced inclusion, together with two controls (cells in PSI and in the vehicle), was subjected to the Western blotting for histone H1. Briefly, the isolated fraction of PSI-induced inclusion was frozen repeatedly with liquid nitrogen, and dissolved with a certain amount of lysing solution consisting of 30 mM Tris, 7 M urea, 2 M thiourea, 4% 3-[(3-cholamidopropyl) -dimethylammonio]-1-propanesulphonate (CHAPS; W/V), 60 mM dithiothreitol (DTT), and proteinase inhibitors. The mixture was incubated, concussed, and collected by centrifugation at 25,000 × g, 4°C for 30 min. Approximately 20 μg of protein extracts adjusted to a total volume of 20 μl was resolved by polyacrylamide gel electrophoresis in a gel buffer. A 0.5-mm-thick discontinuous polyacrylamide gel system without stacking gel layer was determined by 0.1% sodium dodecyl sulfate (SDS; W/V), 15% total gel (T; W/V), and 2.6% cross-linking agent (C; W/W). Protein markers with a range of 23-132 kD were used to measure molecular masses of the resolved proteins. After the gel was transferred to a polyvinylidene difluoride membrane, the membrane was blocked in 5% BSA in PBS-T at 37°C for 1 h, incubated with primary antibody at 1:100 dilution in 1% BSA in PBS-T at 4°C overnight and incubated with secondary antibody at 1:500 dilution in 1% BSA in PBS-T at 37°C for 2 h. The blotted membrane was scanned using a Typhoon 9400 fluorescent laser scanner (Emission filter at 580 BP Cy3 mode, wavelength at 532 nm; Amersham Biosciences) with Typhoon Scanner Control Version 3.0 (Amersham Biosciences). The digitalized image of the immunoblot was analyzed with DeCyder Image QuantTM Version 5.0 (Amersham Biosciences). Bands of histone H1 in image were densitometrically quantified using ImageQuant Version 5.0 (Amersham Biosciences). Dilutions of both primary and secondary antibodies were according to the reference to manufacturer's instructions and the description in literature [26, 27]. Control blotting membrane was carried out, as described above, excluding primary antibody in 1% BSA in PBS-T. Measurements were repeated at least three times.
Protein extraction, 2-D gel electrophoresis and image analysis
Protein extraction, 2-D gel electrophoresis and image analysis were carried out as described elsewhere [25, 106]. Briefly, the isolated fraction of PSI-induced inclusion, frozen repeatedly with liquid nitrogen, was dissolved with a lysis buffer consisting of 30 mM Tris, 7 M urea, 2 M thiourea, 4% CHAPS, 60 mM DTT, 2% pharmalyte (Ph 3.0-10.0; V/V) and proteinase inhibitors. The mixture was incubated, sonicated, and collected by centrifugation at 25,000 × g, 4°C for 30 min. A certain amount of protein extracts prepared from the isolated fraction of PSI-induced inclusion, together with two controls prepared from cells in PSI and the vehicle, were demineralized with 2-D Clean-Up kit, re-dissolved with a rehydration solution consisting of 8 M urea, 2% CHAPS (W/V), 0.6% DTT (W/V), and 0.5% immobilized pH gradients buffer (V/V), and applied to a non-linear Immobiline™ DryStrip IPG gel strip (pH 3.0-10.0; 24 cm; Amersham Biosciences). The first dimension electrophoresis was run on an Ettan IPGphor II Isoelectric Focusing Unit (50 μA per strip; Amersham Biosciences). The strip was then equilibrated in a loading solution consisting of 50 mM Tris-HCl (pH 8.8), 6 M urea, 2% SDS, 30% glycerol, 2% DTT and a trace of bromophenol blue, re-equilibrated in the same loading solution including 4% (W/V) iodoacetamide but excluding DTT, and placed onto the top of polyacrylamide gel (24 × 20 cm2). A 1-mm-thick continuous polyacrylamide gel system without stacking gel layer was determined by 0.1% SDS, 12.5% T, and 2.6% C. The protein markers were used to mark positions of proteins resolved in gel. The second dimension electrophoresis was run on an Ettan DALT six electrophoresis unit (2 W per gel, 600 V, 400 mA; Amersham Biosciences). Coomassie blue-stained gels were scanned using an Umax CE scanner (Amersham Biosciences) with Image Master Labscan version 3.01b (Amersham Biosciences). The digitalized image of the gels was analyzed with Image Master 2-D Evolution version 2003.02 (Amersham Biosciences). Spots in images were densitometrically quantified and statistically evaluated by pattern analysis of computer-assisted pit assessment to detect whether spots appeared reproducibly significant in at least 3 of the 4 gels. These protein spots of interest were selected for MS analysis. If a spot was not detected in at least 3 of the 4 gels, it was considered to be negligible in the present experimental condition.
In-gel digestion, MS and database search
In-gel digestion, MS and database search were carried out as described elsewhere [25, 107]. Briefly, using an Ettan Spot Picker robotic workstation (Amersham Biosciences), the protein spots of interest were automatically selected, excised and placed in 96-well plates at a gel plug per well. Using an Ettan TA Digester robotic workstation (Amersham Biosciences), the gel plugs were twice destained, dehydrated, desiccated and incubated in 10 μl of 1 μg/μl modified porcine trypsin at 4°C overnight, and after which the digested peptide fragments were extracted twice and the two combined extracts were desiccated in other 96-well plates. Using an Ettan Spotter robotic workstation (Amersham Biosciences), 0.3 μl of the digested peptide fragments and an equal volume of 4 μg/μl α-cyano-4-hydroxy-transcinnamic acid were deposited on the surface of a sample slide (Amersham Biosciences). The pre-mix was allowed at room temperature to facilitate uniform dispersion of the digested peptide fragments in a large mix.
Signals of MS were recorded in the positive ion reflection mode on a MALDI-TOF Pro workstation (Amersham Biosciences). The preset threshold values suitable for acquiring and processing MS were referred to our previous requirements . Additionally, the most intensive signals of MS had to be characterized by at least 3 to 5 strongest peaks. Such an additional criterion can efficiently distinguish the target protein from the interference background, since experimental spectra for protein identification consist of the mass and intensity pairs, one pair for each peak .
Protein identification via PMF was initially accomplished using the ProFound search engine against the latest version of the single NCBInr database (fully integrated and included in the Pro workstation or at http://prowl.rockefeller.edu/prowl-cgi/profound.exe), and was further enhanced using Mowse score-based Mascot search engine against the latest version of the multiple NCBInr, SwissProt, MSDB databases http://www.matrixscience.com/search_form_select.html. In the initial identification, the requirements of evaluation standard were allowed as follows: sequence coverage of at least 20%, expectation as much as 0.05, a set of at least 5 matched peptides, and a gap of at least 3 peptides between the accepted protein candidate and the first excluded one in the list of protein candidates provided by the single NCBInr database . For the enhancement of identification, except that mass tolerance at ± 0.2 D as a preset start-up value of searching parameter for the single database is different from mass tolerance at ± 0.1 D for the multiple databases, the others were identical in the two types of protein databases . A protein, if assigned as the identical protein candidate against the two types of protein databases, was ultimately determined.
Cells exposed to PSI for 12, 24, 36 and 48 h, respectively, and a fraction of inclusions isolated from cells in PSI for 48 h were first subjected to the P4HB immunostaining and then the H&E histological staining. The dilutions of both primary (1:40) and secondary (1:100) antibodies were carried out according to the reference to manufacturer's instructions and the description in literature .
eukaryotic elongation factor 2
- χ2 test:
Chi square test
bovine serum albumin
- C, Z-SOD:
Cu, Zn superoxide dismutase
the ER associated degradation pathway
- F1-ATPase beta:
ATP synthase beta subunit
heat shock cognate protein
heat shock protein
the mitochondria-associated degradation pathway
matrix-assisted laser desorption/ionization time-of-flight
prolyl-4-hydroxylase beta subunit
phosphate-buffered saline containing Triton X-100
the protein disulfide isomerase
peptide mass fingerprinting
synthetic proteasome inhibitor
proteasome 26 S subunit ATPase 2
reactive oxygen species
sodium dodecyl sulfate
the substantia nigra pars compacta
Tris-buffered saline solution
T-complex polypeptide 1 beta subunit
ubiquitin proteasome system
ubiquinol-cytochrome c reductase core protein 1
the ubiquitin proteasome pathway.
We thank both Prof. Fengchen Ge and Prof. Yunbo Xue (Apiculture Science Institute of Jilin Province, Jilin, China) for their technical assistance.
- Roth J, Yam GH, Fan J, Hirano K, Gaplovska-Kysela K, Le Fourn V, Guhl B, Santimaria R, Torossi T, Ziak M, Zuber C: Protein quality control: the who's who, the where's and therapeutic escapes. Histochem Cell Biol. 2008, 129: 163-177. 10.1007/s00418-007-0366-7.PubMed CentralPubMedGoogle Scholar
- Outeiro TF, Tetzlaff J: Mechanisms of disease II: cellular protein quality control. Semin Pediatr Neurol. 2007, 14: 15-25. 10.1016/j.spen.2006.11.005.PubMedGoogle Scholar
- Groothuis TA, Dantuma NP, Neefjes J, Salomons FA: Ubiquitin crosstalk connecting cellular processes. Cell Div. 2006, 1: 21-10.1186/1747-1028-1-21.PubMed CentralPubMedGoogle Scholar
- McNaught KS, Olanow CW: Protein aggregation in the pathogenesis of familial and sporadic Parkinson's disease. Neurobiol Aging. 2006, 27: 530-545. 10.1016/j.neurobiolaging.2005.08.012.PubMedGoogle Scholar
- Segref A, Hoppe T: Think locally: control of ubiquitin-dependent protein degradation in neurons. EMBO Rep. 2009, 10: 44-50. 10.1038/embor.2008.229.PubMed CentralPubMedGoogle Scholar
- Garcia-Mata R, Gao YS, Sztul E: Hassles with taking out the garbage: aggravating aggresomes. Traffic. 2002, 3: 388-396. 10.1034/j.1600-0854.2002.30602.x.PubMedGoogle Scholar
- Forno LS: Neuropathology of Parkinson's disease. J Neuropathol Exp Neurol. 1996, 55: 259-272. 10.1097/00005072-199603000-00001.PubMedGoogle Scholar
- Ross CA, Poirier MA: Protein aggregation and neurodegenerative disease. Nat Med. 2004, S10-17. 10.1038/nm1066. Suppl
- Fornai F, Lenzi P, Gesi M, Soldani P, Ferrucci M, Lazzeri G, Capobianco L, Battaglia G, De Blasi A, Nicoletti F, Paparelli A: Methamphetamine produces neuronal inclusions in the nigrostriatal system and in PC12 cells. J Neurochem. 2004, 88: 114-123. 10.1046/j.1471-4159.2003.02137.x.PubMedGoogle Scholar
- Dev KK, Hofele K, Barbieri S, Buchman VL, van der Putten H: Part II: alpha-synuclein and its molecular pathophysiological role in neurodegenerative disease. Neuropharmacology. 2003, 45: 14-44. 10.1016/S0028-3908(03)00140-0.PubMedGoogle Scholar
- McNaught KS, Shashidharan P, Perl DP, Jenner P, Olanow CW: Aggresome-related biogenesis of Lewy bodies. Eur J Neurosci. 2002, 16: 2136-2148. 10.1046/j.1460-9568.2002.02301.x.PubMedGoogle Scholar
- Taylor JP, Tanaka F, Robitschek J, Sandoval CM, Taye A, Markovic-Plese S, Fischbeck KH: Aggresomes protect cells by enhancing the degradation of toxic polyglutamine-containing protein. Hum Mol Genet. 2003, 12: 749-757. 10.1093/hmg/ddg074.PubMedGoogle Scholar
- Olzmann JA, Li L, Chin LS: Aggresome formation and neurodegenerative diseases: therapeutic implications. Curr Med Chem. 2008, 15: 47-60. 10.2174/092986708783330692.PubMed CentralPubMedGoogle Scholar
- Yew EH, Cheung NS, Choy MS, Qi RZ, Lee AY, Peng ZF, Melendez AJ, Manikandan J, Koay ES, Chiu LL, Ng WL, Whiteman M, Kandiah J, Halliwell B: Proteasome inhibition by lactacystin in primary neuronal cells induces both potentially neuroprotective and pro-apoptotic transcriptional responses: a microarray analysis. J Neurochem. 2005, 94: 943-956. 10.1111/j.1471-4159.2005.03220.x.PubMedGoogle Scholar
- Peng ZF, Chen MJ, Yap YW, Manikandan J, Melendez AJ, Choy MS, Moore PK, Cheung NS: Proteasome inhibition: an early or late event in nitric oxide-induced neuronal death?. Nitric Oxide. 2008, 18: 136-145. 10.1016/j.niox.2007.11.002.PubMedGoogle Scholar
- Wang Y, Meriin AB, Zaarur N, Romanova NV, Chernoff YO, Costello CE, Sherman MY: Abnormal proteins can form aggresome in yeast: aggresome-targeting signals and components of the machinery. FASEB J. 2009, 23: 451-463. 10.1096/fj.08-117614.PubMed CentralPubMedGoogle Scholar
- Gregersen N: Protein misfolding disorders: pathogenesis and intervention. J Inherit Metab Dis. 2006, 29: 456-470. 10.1007/s10545-006-0301-4.PubMedGoogle Scholar
- Ebadi M, Pfeiffer RF: Parkinson's disease. Texas (USA): Culinary and Hospitality Industry Publications Services. 2005, 132: [http://www.chipsbooks.com/parkdis.htm]Google Scholar
- Zhou Y, Gu G, Goodlett DR, Zhang T, Pan C, Montine TJ, Montine KS, Aebersold RH, Zhang J: Analysis of alpha-synuclein-associated proteins by quantitative proteomics. J Biol Chem. 2004, 279: 39155-39164. 10.1074/jbc.M405456200.PubMedGoogle Scholar
- Leverenz JB, Umar I, Wang Q, Montine TJ, McMillan PJ, Tsuang DW, Jin J, Pan C, Shin J, Zhu D, Zhang J: Proteomic identification of novel proteins in cortical Lewy bodies. Brain Pathol. 2007, 17: 139-145. 10.1111/j.1750-3639.2007.00048.x.PubMedGoogle Scholar
- Xia Q, Liao L, Cheng D, Duong DM, Gearing M, Lah JJ, Levey AI, Peng J: Proteomic identification of novel proteins associated with Lewy bodies. Front Biosci. 2008, 13: 3850-3856. 10.2741/2973.PubMed CentralPubMedGoogle Scholar
- Guimarães de Araújo ME, Huber LA: Subcellular fractionation. Methods Mol Biol. 2007, 357: 73-85.Google Scholar
- McNaught KS, Belizaire R, Jenner P, Olanow CW, Isacson O: Selective loss of 20 S proteasome alpha-subunits in the substantia nigra pars compacta in Parkinson's disease. Neurosci Lett. 2002, 326: 155-158. 10.1016/S0304-3940(02)00296-3.PubMedGoogle Scholar
- Rideout HJ, Larsen KE, Sulzer D, Stefanis L: Proteasomal inhibition leads to formation of ubiquitin/alpha-synuclein-immunoreactive inclusions in PC12 cells. J Neurochem. 2001, 78: 899-908. 10.1046/j.1471-4159.2001.00474.x.PubMedGoogle Scholar
- Li X, Zhang Y, Hu Y, Chang M, Liu T, Wang D, Zhang Y, Zhang L, Hu L: Chaperone proteins identified from synthetic proteasome inhibitor-induced inclusions in PC12 cells by proteomic analysis. Acta Biochim Biophys Sin (Shanghai). 2008, 40: 406-418. 10.1111/j.1745-7270.2008.00416.x.Google Scholar
- Hendzel MJ, Nishioka WK, Raymond Y, Allis CD, Bazett-Jones DP, Th'ng JP: Chromatin condensation is not associated with apoptosis. J Biol Chem. 1998, 273: 24470-24478. 10.1074/jbc.273.38.24470.PubMedGoogle Scholar
- Wondrak GT, Cervantes-Laurean D, Jacobson EL, Jacobson MK: Histone carbonylation in vivo and in vitro. Biochem J. 2000, 351: 769-777. 10.1042/0264-6021:3510769.PubMed CentralPubMedGoogle Scholar
- Tofaris GK, Razzaq A, Ghetti B, Lilley KS, Spillantini MG: Ubiquitination of alpha-synuclein in Lewy bodies is a pathological event not associated with impairment of proteasome function. J Biol Chem. 2003, 278: 44405-44411. 10.1074/jbc.M308041200.PubMedGoogle Scholar
- Anderson JP, Walker DE, Goldstein JM, de Laat R, Banducci K, Caccavello RJ, Barbour R, Huang J, Kling K, Lee M, Diep L, Keim PS, Shen X, Chataway T, Schlossmacher MG, Seubert P, Schenk D, Sinha S, Gai WP, Chilcote TJ: Phosphorylation of Ser-129 is the dominant pathological modification of alpha-synuclein in familial and sporadic Lewy body disease. J Biol Chem. 2006, 281: 29739-29752. 10.1074/jbc.M600933200.PubMedGoogle Scholar
- Wang L, Li D, Bao C, You J, Wang Z, Shi Y, Zhang H: Ultrasonic extraction and separation of anthraquinones from Rheum palmatum L. Ultrason Sonochem. 2008, 15: 738-746. 10.1016/j.ultsonch.2007.12.008.PubMedGoogle Scholar
- Witzmann FA, Arnold RJ, Bai F, Hrncirova P, Kimpel MW, Mechref YS, McBride WJ, Novotny MV, Pedrick NM, Ringham HN, Simon JR: A proteomic survey of rat cerebral cortical synaptosomes. Proteomics. 2005, 5: 2177-2201. 10.1002/pmic.200401102.PubMed CentralPubMedGoogle Scholar
- Jin BF, He K, Wang HX, Wang J, Zhou T, Lan Y, Hu MR, Wei KH, Yang SC, Shen BF, Zhang XM: Proteomic analysis of ubiquitin-proteasome effects: insight into the function of eukaryotic initiation factor 5A. Oncogene. 2003, 22: 4819-4830. 10.1038/sj.onc.1206738.PubMedGoogle Scholar
- Mimnaugh EG, Xu W, Vos M, Yuan X, Isaacs JS, Bisht KS, Gius D, Neckers L: Simultaneous inhibition of hsp 90 and the proteasome promotes protein ubiquitination, causes endoplasmic reticulum-derived cytosolic vacuolization, and enhances antitumor activity. Expert Rev Proteomics. 2004, 1: 207-217. 10.1586/147894126.96.36.199.Google Scholar
- Kakhniashvili DG, Griko NB, Bulla LA, Goodman SR: The proteomics of sickle cell disease: profiling of erythrocyte membrane proteins by 2D-DIGE and tandem mass spectrometry. Exp Biol Med (Maywood). 2005, 230: 787-792.Google Scholar
- Nakashima S, Ikuta F: Tyrosine hydroxylase protein in Lewy bodies of parkinsonian and senile brains. J Neurol Sci. 1984, 66: 91-96. 10.1016/0022-510X(84)90144-8.PubMedGoogle Scholar
- Ostrerova N, Petrucelli L, Farrer M, Mehta N, Choi P, Hardy J, Wolozin B: alpha-Synuclein shares physical and functional homology with 14-3-3 proteins. J Neurosci. 1999, 19: 5782-5791.PubMedGoogle Scholar
- Alim MA, Hossain MS, Arima K, Takeda K, Izumiyama Y, Nakamura M, Kaji H, Shinoda T, Hisanaga S, Ueda K: Tubulin seeds alpha-synuclein fibril formation. J Biol Chem. 2002, 277: 2112-2117. 10.1074/jbc.M102981200.PubMedGoogle Scholar
- Hayashida K, Oyanagi S, Mizutani Y, Yokochi M: An early cytoplasmic change before Lewy body maturation: an ultrastructural study of the substantia nigra from an autopsy case of juvenile parkinsonism. Acta Neuropathol. 1993, 85: 445-448. 10.1007/BF00334457.PubMedGoogle Scholar
- Gai WP, Yuan HX, Li XQ, Power JT, Blumbergs PC, Jensen PH: In situ and in vitro study of colocalization and segregation of alpha-synuclein, ubiquitin, and lipids in Lewy bodies. Exp Neurol. 2000, 166: 324-333. 10.1006/exnr.2000.7527.PubMedGoogle Scholar
- Shibata N, Hirano A, Kobayashi M, Sasaki S, Kato T, Matsumoto S: Cu/Zn superoxide dismutase-like immunoreactivity in Lewy body-like inclusions of sporadic amyotrophic lateral sclerosis. Neurosci Lett. 1994, 179: 149-152. 10.1016/0304-3940(94)90956-3.PubMedGoogle Scholar
- Nishiyama K, Murayama S, Shimizu J, Ohya Y, Kwak S, Asayama K, Kanazawa I: Cu/Zn superoxide dismutase-like immunoreactivity is present in Lewy bodies from Parkinson disease: a light and electron microscopic immunocytochemical study. Acta Neuropathol. 1995, 89: 471-474. 10.1007/BF00571500.PubMedGoogle Scholar
- Ii K, Ito H, Tanaka K, Hirano A: Immunocytochemical co-localization of the proteasome in ubiquitinated structures in neurodegenerative diseases and the elderly. J Neuropathol Exp Neurol. 1997, 56: 125-131. 10.1097/00005072-199702000-00002.PubMedGoogle Scholar
- Outeiro TF, Klucken J, Strathearn KE, Liu F, Nguyen P, Rochet JC, Hyman BT, McLean PJ: Small heat shock proteins protect against alpha-synuclein-induced toxicity and aggregation. Biochem Biophys Res Commun. 2006, 351: 631-638. 10.1016/j.bbrc.2006.10.085.PubMed CentralPubMedGoogle Scholar
- Schipper HM, Liberman A, Stopa EG: Neural heme oxygenase-1 expression in idiopathic Parkinson's disease. Exp Neurol. 1998, 50: 60-68. 10.1006/exnr.1997.6752.Google Scholar
- Richard M, Biacabe AG, Streichenberger N, Ironside JW, Mohr M, Kopp N, Perret-Liaudet A: Immunohistochemical localization of 14.3.3 zeta protein in amyloid plaques in human spongiform encephalopathies. Acta Neuropathol. 2003, 105: 296-302.PubMedGoogle Scholar
- Kaneko K, Hachiya NS: The alternative role of 14-3-3 zeta as a sweeper of misfolded proteins in disease conditions. Med Hypotheses. 2006, 67: 169-171. 10.1016/j.mehy.2006.01.019.PubMedGoogle Scholar
- Imai Y, Soda M, Murakami T, Shoji M, Abe K, Takahashi R: A product of the human gene adjacent to parkin is a component of Lewy bodies and suppresses Pael receptor-induced cell death. J Biol Chem. 2003, 278: 51901-51910. 10.1074/jbc.M309655200.PubMedGoogle Scholar
- Hirabayashi M, Inoue K, Tanaka K, Nakadate K, Ohsawa Y, Kamei Y, Popiel AH, Sinohara A, Iwamatsu A, Kimura Y, Uchiyama Y, Hori S, Kakizuka A: VCP/p97 in abnormal protein aggregates, cytoplasmic vacuoles, and cell death, phenotypes relevant to neurodegeneration. Cell Death Differ. 2001, 8: 977-984. 10.1038/sj.cdd.4400907.PubMedGoogle Scholar
- Rideout HJ, Stefanis L: Proteasomal inhibition-induced inclusion formation and death in cortical neurons require transcription and ubiquitination. Mol Cell Neurosci. 2002, 21: 223-238. 10.1006/mcne.2002.1173.PubMedGoogle Scholar
- Fornai F, Lenzi P, Gesi M, Ferrucci M, Lazzeri G, Busceti CL, Ruffoli R, Soldani P, Ruggieri S, Alessandri MG, Paparelli A: Fine structure and biochemical mechanisms underlying nigrostriatal inclusions and cell death after proteasome inhibition. J Neurosci. 2003, 23: 8955-8966.PubMedGoogle Scholar
- Lang-Rollin I, Maniati M, Jabado O, Vekrellis K, Papantonis S, Rideout HJ, Stefanis L: Apoptosis and the conformational change of Bax induced by proteasomal inhibition of PC12 cells are inhibited by bcl-xL and bcl-2. Apoptosis. 2005, 10: 809-820. 10.1007/s10495-005-0378-5.PubMedGoogle Scholar
- Zhang L, Chang M, Li H, Hou S, Zhang Y, Hu Y, Han W, Hu L: Proteomic changes of PC12 cells treated with proteasomal inhibitor PSI. Brain Res. 2007, 1153: 196-203. 10.1016/j.brainres.2007.03.073.PubMedGoogle Scholar
- Tse DC, McCreery RL, Adams RN: Potential oxidative pathways of brain catecholamines. J Med Chem. 1976, 19: 37-40. 10.1021/jm00223a008.PubMedGoogle Scholar
- Keller JN, Dimayuga E, Chen Q, Thorpe J, Gee J, Ding Q: Autophagy, proteasomes, lipofuscin, and oxidative stress in the aging brain. Int J Biochem Cell Biol. 2004, 36: 2376-2391. 10.1016/j.biocel.2004.05.003.PubMedGoogle Scholar
- Pigeon D, Ferrara P, Gros F, Thibault J: Rat pheochromocytoma tyrosine hydroxylase is phosphorylated on serine 40 by an associated protein kinase. J Biol Chem. 1987, 262: 6155-6158.PubMedGoogle Scholar
- Peng X, Tehranian R, Dietrich P, Stefanis L, Perez RG: Alpha-synuclein activation of protein phosphatase 2A reduces tyrosine hydroxylase phosphorylation in dopaminergic cells. J Cell Sci. 2005, 118: 3523-3530. 10.1242/jcs.02481.PubMedGoogle Scholar
- Døskeland AP, Flatmark T: Ubiquitination of soluble and membrane-bound tyrosine hydroxylase and degradation of the soluble form. Eur J Biochem. 2002, 269: 1561-1569. 10.1046/j.1432-1033.2002.02808.x.PubMedGoogle Scholar
- Lopez Verrilli MA, Pirola CJ, Pascual MM, Dominici FP, Turyn D, Gironacci MM: Angiotensin-(1-7) through AT receptors mediates tyrosine hydroxylase degradation via the ubiquitin-proteasome pathway. J Neurochem. 2009, 109: 326-335. 10.1111/j.1471-4159.2009.05912.x.PubMedGoogle Scholar
- Muratani M, Tansey WP: How the ubiquitin-proteasome system controls transcription. Nat Rev Mol Cell Biol. 2003, 4: 192-201. 10.1038/nrm1049.PubMedGoogle Scholar
- Zimmermann J, Erdmann D, Lalande I, Grossenbacher R, Noorani M, Fürst P: Proteasome inhibitor induced gene expression profiles reveal overexpression of transcriptional regulators ATF3, GADD153 and MAD1. Oncogene. 2000, 19: 2913-2920. 10.1038/sj.onc.1203606.PubMedGoogle Scholar
- Yu ZX, Li SH, Nguyen HP, Li XJ: Huntingtin inclusions do not deplete polyglutamine-containing transcription factors in HD mice. Hum Mol Genet. 2002, 11: 905-914. 10.1093/hmg/11.8.905.PubMedGoogle Scholar
- Rajan RS, Illing ME, Bence NF, Kopito RR: Specificity in intracellular protein aggregation and inclusion body formation. Proc Natl Acad Sci USA. 2001, 98: 13060-13065. 10.1073/pnas.181479798.PubMed CentralPubMedGoogle Scholar
- Redpath NT, Foulstone EJ, Proud CG: Regulation of translation elongation factor-2 by insulin via a rapamycin-sensitive signalling pathway. EMBO J. 1996, 15: 2291-2297.PubMed CentralPubMedGoogle Scholar
- Arora S, Yang JM, Hait WN: Identification of the ubiquitin-proteasome pathway in the regulation of the stability of eukaryotic elongation factor-2 kinase. Cancer Res. 2005, 65: 3806-3810. 10.1158/0008-5472.CAN-04-4036.PubMedGoogle Scholar
- Ren Y, Zhao J, Feng J: Parkin binds to alpha/beta tubulin and increases their ubiquitination and degradation. J Neurosci. 2003, 23: 3316-3324.PubMed CentralPubMedGoogle Scholar
- Domingues AF, Arduíno DM, Esteves AR, Swerdlow RH, Oliveira CR, Cardoso SM: Mitochondria and ubiquitin-proteasomal system interplay: relevance to Parkinson's disease. Free Radic Biol Med. 2008, 45: 820-805. 10.1016/j.freeradbiomed.2008.06.007.PubMedGoogle Scholar
- Sullivan PG, Dragicevic NB, Deng JH, Bai Y, Dimayuga E, Ding Q, Chen Q, Bruce-Keller AJ, Keller JN: Proteasome inhibition alters neural mitochondrial homeostasis and mitochondria turnover. J Biol Chem. 2004, 279: 20699-20707. 10.1074/jbc.M313579200.PubMedGoogle Scholar
- Malkus KA, Tsika E, Ischiropoulos H: Oxidative modifications, mitochondrial dysfunction, and impaired protein degradation in Parkinson's disease: how neurons are lost in the Bermuda triangle. Mol Neurodegener. 2009, 4: 24-10.1186/1750-1326-4-24.PubMed CentralPubMedGoogle Scholar
- Muqit MM, Abou-Sleiman PM, Saurin AT, Harvey K, Gandhi S, Deas E, Eaton S, Payne Smith MD, Venner K, Matilla A, Healy DG, Gilks WP, Lees AJ, Holton J, Revesz T, Parker PJ, Harvey RJ, Wood NW, Latchman DS: Altered cleavage and localization of PINK1 to aggresomes in the presence of proteasomal stress. J Neurochem. 2006, 98: 156-169. 10.1111/j.1471-4159.2006.03845.x.PubMedGoogle Scholar
- McBride WH, Iwamoto KS, Syljuasen R, Pervan M, Pajonk F: The role of the ubiquitin/proteasome system in cellular responses to radiation. Oncogene. 2003, 22: 5755-5773. 10.1038/sj.onc.1206676.PubMedGoogle Scholar
- Noor R, Mittal S, Iqbal J: Superoxide dismutase--applications and relevance to human diseases. Med Sci Monit. 2002, 8: 210-215.Google Scholar
- Kang JH, Kim KS: Enhanced oligomerization of the alpha-synuclein mutant by the Cu,Zn-superoxide dismutase and hydrogen peroxide system. Mol Cells. 2003, 15: 87-93.PubMedGoogle Scholar
- Lee MH, Hyun DH, Jenner P, Halliwell B: Effect of proteasome inhibition on cellular oxidative damage, antioxidant defences and nitric oxide production. J Neurochem. 2001, 78: 32-41. 10.1046/j.1471-4159.2001.00416.x.PubMedGoogle Scholar
- Alexandrova A, Petrov L, Georgieva A, Kirkova M, Kukan M: Effects of proteasome inhibitor, MG132, on proteasome activity and oxidative status of rat liver. Cell Biochem Funct. 2008, 26: 392-398. 10.1002/cbf.1459.PubMedGoogle Scholar
- Choi J, Rees HD, Weintraub ST, Levey AI, Chin LS, Li L: Oxidative modifications and aggregation of Cu,Zn-superoxide dismutase associated with Alzheimer and Parkinson diseases. J Biol Chem. 2005, 280: 11648-11655. 10.1074/jbc.M414327200.PubMedGoogle Scholar
- Thorpe JA, Christian PA, Schwarze SR: Proteasome inhibition blocks caspase-8 degradation and sensitizes prostate cancer cells to death receptor-mediated apoptosis. Prostate. 2008, 68: 200-209. 10.1002/pros.20706.PubMedGoogle Scholar
- Sun F, Kanthasamy A, Song C, Yang Y, Anantharam V, Kanthasamy AG: Proteasome inhibitor-induced apoptosis is mediated by positive feedback amplification of PKCdelta proteolytic activation and mitochondrial translocation. J Cell Mol Med. 2008, 12: 2467-2481. 10.1111/j.1582-4934.2008.00293.x.PubMed CentralPubMedGoogle Scholar
- Trimmer PA, Borland MK, Keeney PM, Bennett JP, Parker WD: Parkinson's disease transgenic mitochondrial cybrids generate Lewy inclusion bodies. J Neurochem. 2004, 88: 800-812. 10.1046/j.1471-4159.2003.02168.x.PubMedGoogle Scholar
- Wojcik C, Di Napoli M: Ubiquitin-proteasome system and proteasome inhibition: new strategies in stroke therapy. Stroke. 2004, 35: 1506-1518. 10.1161/01.STR.0000126891.93919.4e.PubMedGoogle Scholar
- Fuchs D, Berges C, Opelz G, Daniel V, Naujokat C: Increased expression and altered subunit composition of proteasomes induced by continuous proteasome inhibition establish apoptosis resistance and hyperproliferation of Burkitt lymphoma cells. J Cell Biochem. 2008, 103: 270-283. 10.1002/jcb.21405.PubMedGoogle Scholar
- Lee CS, Tee LY, Warmke T, Vinjamoori A, Cai A, Fagan AM, Snider BJ: A proteasomal stress response: pre-treatment with proteasome inhibitors increases proteasome activity and reduces neuronal vulnerability to oxidative injury. J Neurochem. 2004, 91: 996-1006. 10.1111/j.1471-4159.2004.02813.x.PubMedGoogle Scholar
- Meiners S, Heyken D, Weller A, Ludwig A, Stangl K, Kloetzel PM, Krüger E: Inhibition of proteasome activity induces concerted expression of proteasome genes and de novo formation of Mammalian proteasomes. J Biol Chem. 2003, 278: 21517-21525. 10.1074/jbc.M301032200.PubMedGoogle Scholar
- Seo H, Sonntag KC, Isacson O: Generalized brain and skin proteasome inhibition in Huntington's disease. Ann Neurol. 2004, 56: 319-328. 10.1002/ana.20207.PubMedGoogle Scholar
- McNaught KS, Jackson T, JnoBaptiste R, Kapustin A, Olanow CW: Proteasomal dysfunction in sporadic Parkinson's disease. Neurology. 2006, 66: S37-49. 10.1212/01.wnl.0000221745.58886.2e.PubMedGoogle Scholar
- Mandel S, Grunblatt E, Riederer P, Amariglio N, Jacob-Hirsch J, Rechavi G, Youdim MB: Gene expression profiling of sporadic Parkinson's disease substantia nigra pars compacta reveals impairment of ubiquitin-proteasome subunits, SKP1A, aldehyde dehydrogenase, and chaperone HSC-70. Ann N Y Acad Sci. 2005, 1053: 356-375. 10.1196/annals.1344.031.PubMedGoogle Scholar
- Meimaridou E, Gooljar SB, Chapple JP: From hatching to dispatching: the multiple cellular roles of the Hsp70 molecular chaperonen machinery. J Mol Endocrinol. 2009, 42: 1-9. 10.1677/JME-08-0116.PubMedGoogle Scholar
- Germain D: Ubiquitin-dependent and -independent mitochondrial protein quality controls: implications in ageing and neurodegenerative diseases. Mol Microbiol. 2008, 70: 1334-1341. 10.1111/j.1365-2958.2008.06502.x.PubMedGoogle Scholar
- Bian Q, Fernandes AF, Taylor A, Wu M, Pereira P, Shang F: Expression of K6W-ubiquitin in lens epithelial cells leads to upregulation of a broad spectrum of molecular chaperones. Mol Vis. 2008, 14: 403-412.PubMed CentralPubMedGoogle Scholar
- Hayes SA, Dice JF: Roles of molecular chaperones in protein degradation. J Cell Biol. 1996, 132: 255-258. 10.1083/jcb.132.3.255.PubMedGoogle Scholar
- Morimoto RI: Proteotoxic stress and inducible chaperone networks in neurodegenerative disease and aging. Genes Dev. 2008, 22: 1427-1438. 10.1101/gad.1657108.PubMed CentralPubMedGoogle Scholar
- Slavotinek AM, Biesecker LG: Unfolding the role of chaperones and chaperonnins in human disease. Trend Genet. 2001, 17: 528-535. 10.1016/S0168-9525(01)02413-1.Google Scholar
- Ni M, Lee AS: ER chaperones in mammalian development and human diseases. FEBS Lett. 2007, 581: 3641-3651. 10.1016/j.febslet.2007.04.045.PubMed CentralPubMedGoogle Scholar
- Junn E, Lee SS, Suhr UT, Mouradian MM: Parkin accumulation in aggresomes due to proteasome impairment. J Biol Chem. 2002, 277: 47870-47877. 10.1074/jbc.M203159200.PubMedGoogle Scholar
- Ito H, Kamei K, Iwamoto I, Inaguma Y, García-Mata R, Sztul E, Kato K: Inhibition of proteasomes induces accumulation, phosphorylation, and recruitment of HSP27 and alphaB-crystallin to aggresomes. J Biochem. 2002, 131: 593-603.PubMedGoogle Scholar
- Abou-Sleiman PM, Muqit MM, Wood NW: Expanding insights of mitochondrial dysfunction in Parkinson's disease. Nat Rev Neurosci. 2006, 7 (3): 207-219. 10.1038/nrn1868.PubMedGoogle Scholar
- Koivu J, Myllyla R, Helaakoski T, Pihlajaniemi T, Tasanen K, Kivirikko KI: A single polypeptide acts both as the beta subunit of prolyl 4-hydroxylase and as a protein disulfide-isomerase. J Biol Chem. 1987, 262: 6447-6449.PubMedGoogle Scholar
- Pajunen L, Jones TA, Goddard A, Sheer D, Solomon E, Pihlajaniemi T, Kivirikko KI: Regional assignment of the human gene coding for a multifunctional polypeptide (P4HB) acting as the beta-subunit of prolyl 4-hydroxylase and the enzyme protein disulfide isomerase to 17q25. Cytogenet Cell Genet. 1991, 56: 165-168. 10.1159/000133078.PubMedGoogle Scholar
- Hatahet F, Ruddock LW: Substrate recognition by the protein disulfide isomerases. FEBS J. 2007, 274: 5223-5234. 10.1111/j.1742-4658.2007.06058.x.PubMedGoogle Scholar
- Molinari M, Galli C, Piccaluga V, Pieren M, Paganetti P: Sequential assistance of molecular chaperones and transient formation of covalent complexes during protein degradation from the ER. J Cell Biol. 2002, 158: 247-257. 10.1083/jcb.200204122.PubMed CentralPubMedGoogle Scholar
- Conn KJ, Gao W, McKee A, Lan MS, Ullman MD, Eisenhauer PB, Fine RE, Wells JM: Identification of the protein disulfide isomerase family member PDIp in experimental Parkinson's disease and Lewy body pathology. Brain Res. 2004, 1022: 164-172. 10.1016/j.brainres.2004.07.026.PubMedGoogle Scholar
- Ribble D, Goldstein NB, Norris DA, Shellman YG: A simple technique for quantifying apoptosis in 96-well plates. BMC Biotechnol. 2005, 5: 12-10.1186/1472-6750-5-12.PubMed CentralPubMedGoogle Scholar
- Xu Q, Kanthasamy AG, Reddy MB: Neuroprotective effect of the natural iron chelator, phytic acid in a cell culture model of Parkinson's disease. Toxicology. 2008, 245: 101-108. 10.1016/j.tox.2007.12.017.PubMedGoogle Scholar
- Kikuchi S, Shinpo K, Tsuji S, Takeuchi M, Yamagishi S, Makita Z, Niino M, Yabe I, Tashiro K: Effect of proteasome inhibitor on cultured mesencephalic dopaminergic neurons. Brain Res. 2003, 964: 228-236. 10.1016/S0006-8993(02)04030-1.PubMedGoogle Scholar
- Fan HM, Yang L, Xie QF, Han XY, Wu M, Zhang FC, Yao CL, Li G, Gao ZL: Hepatitis B virus × protein suppressing adriamycin-induced apoptosis of HepG2 cells. Zhonghua Gan Zang Bing Za Zhi. 2008, 16: 25-28.PubMedGoogle Scholar
- Lee HJ, Lee SJ: Characterization of cytoplasmic alpha-synuclein aggregates. Fibril formation is tightly linked to the inclusion-forming process in cells. J Biol Chem. 2002, 277: 48976-48983. 10.1074/jbc.M208192200.PubMedGoogle Scholar
- Jones AR, Gibson F: An update on data standards for gel electrophoresis. Proteomics. 2007, 7 (Suppl 1): 35-40. 10.1002/pmic.200700171.PubMedGoogle Scholar
- Taylor CF, Paton NW, Lilley KS, Binz PA, Julian RK, Jones AR, Zhu W, Apweiler R, Aebersold R, Deutsch EW, Dunn MJ, Heck AJ, Leitner A, Macht M, Mann M, Martens L, Neubert TA, Patterson SD, Ping P, Seymour SL, Souda P, Tsugita A, Vandekerckhove J, Vondriska TM, Whitelegge JP, Wilkins MR, Xenarios I, Yates JR, Hermjakob H: The minimum information about a proteomics experiment (MIAPE). Nat Biotechnol. 2007, 25: 887-893. 10.1038/nbt1329.PubMedGoogle Scholar
- Colinge J: Peptide fragment intensity statistical modeling. Anal Chem. 2007, 79: 7286-7290. 10.1021/ac070488n.PubMedGoogle Scholar
- Grimmer C, Balbus N, Lang U, Aigner T, Cramer T, Müller L, Swoboda B, Pfander D: Regulation of type II collagen synthesis during osteoarthritis by prolyl-4-hydroxylases: possible influence of low oxygen levels. J Pathol. 2006, 169: 491-502.Google Scholar
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.